{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:38:52Z","timestamp":1782337132643,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,18]]},"DOI":"10.7759\/cureus.50726","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T15:05:40Z","timestamp":1702911940000},"source":"Crossref","is-referenced-by-count":7,"title":["Paradoxical Psoriasis and Worsening Spondylitis Due to Secukinumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Khalid A","family":"Alnaqbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Al Zeyoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M","family":"Alhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Jassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima A","family":"Albreiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00932-5","article-title":"Work disability in axial spondyloarthritis","volume":"22","author":"Nikiphorou E","year":"2020","unstructured":"Nikiphorou E, Ramiro S. Work disability in axial spondyloarthritis. Curr Rheumatol Rep. 2020, 22:55. 10.1007\/s11926-020-00932-5","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al.. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023, 82:19-34. 10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot \u00c9","year":"2016","unstructured":"Toussirot \u00c9, Aubin F. Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016, 2:e000239. 10.1136\/rmdopen-2015-000239","journal-title":"RMD Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/11597710-000000000-00000","article-title":"Paradoxical and bidirectional drug effects","volume":"35","author":"Smith SW","year":"2012","unstructured":"Smith SW, Hauben M, Aronson JK. Paradoxical and bidirectional drug effects. Drug Saf. 2012, 35:173-89. 10.2165\/11597710-000000000-00000","journal-title":"Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich S","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019, 10:282. 10.3389\/fphar.2019.00282","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead318","article-title":"The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study","volume":"62","author":"Yagiz B","year":"2023","unstructured":"Yagiz B, Lermi N, Coskun BN, et al.. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study. Rheumatology (Oxford). 2023, 62:3962-7. 10.1093\/rheumatology\/kead318","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2016.10.002","article-title":"Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab","volume":"35","author":"Su P","year":"2017","unstructured":"Su P, Pan JY. Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab. Dermatol Sinica. 2017, 35:112-3. 10.1016\/j.dsi.2016.10.002","journal-title":"Dermatol Sinica"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12505","article-title":"Anti IL-17 flared psoriasis in a patient on secukinumab","volume":"30","author":"Noell C","year":"2017","unstructured":"Noell C, McQuade B, Gottlieb A, Rosmarin D. Anti IL-17 flared psoriasis in a patient on secukinumab. Dermatol Ther. 2017, 30:10.1111\/dth.12505","journal-title":"Dermatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2826","article-title":"Secukinumab-induced psoriasiform eruption","volume":"153","author":"Sladden MJ","year":"2017","unstructured":"Sladden MJ, Sladden CS, Gulliver WP. Secukinumab-induced psoriasiform eruption. JAMA Dermatol. 2017, 153:1194-5. 10.1001\/jamadermatol.2017.2826","journal-title":"JAMA Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13375","article-title":"Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab","volume":"43","author":"Hoshina D","year":"2018","unstructured":"Hoshina D, Haga N, Furuya K, Sakai M. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab. Clin Exp Dermatol. 2018, 43:718-9. 10.1111\/ced.13375","journal-title":"Clin Exp Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1203","article-title":"Two cases of anti-interleukin-17 flared psoriasis","volume":"79","author":"Prussick L","year":"2018","unstructured":"Prussick L, Noell C, Her M, Alomran A, Abudu M, Rosmarin D. Two cases of anti-interleukin-17 flared psoriasis. J Am Acad Dermatol. 2018, 79:10. 10.1016\/j.jaad.2018.05.1203","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra S","year":"2019","unstructured":"Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2019, 44:72-3. 10.1111\/ced.13731","journal-title":"Clin Exp Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2019.1594359","article-title":"New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report","volume":"49","author":"Currado D","year":"2020","unstructured":"Currado D, Margiotta D, Conforti C, Coppola R, Panasiti V, Afeltra A, Navarini L. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report. Scand J Rheumatol. 2020, 49:75-6. 10.1080\/03009742.2019.1594359","journal-title":"Scand J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15082","article-title":"Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab","volume":"46","author":"Honma M","year":"2019","unstructured":"Honma M, Nozaki H, Hayashi K, Iinuma S, Ishida-Yamamoto A. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab. J Dermatol. 2019, 46:e468-9. 10.1111\/1346-8138.15082","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3702","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases","volume":"30","author":"M\u00f6ssner R","year":"2020","unstructured":"M\u00f6ssner R, Pinter A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol. 2020, 30:177-8. 10.1684\/ejd.2020.3702","journal-title":"Eur J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001076","article-title":"Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment","volume":"26","author":"Abbruzzese A","year":"2020","unstructured":"Abbruzzese A, Venerito V, Lopalco G, Fornaro M, Giannotta M, Iannone F. Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment. J Clin Rheumatol. 2020, 26:e208-9. 10.1097\/RHU.0000000000001076","journal-title":"J Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13504","article-title":"Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient","volume":"33","author":"Durmaz K","year":"2020","unstructured":"Durmaz K, Ataseven A, Ozer I. Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient. Dermatol Ther. 2020, 33:e13504. 10.1111\/dth.13504","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14639","article-title":"Palmoplantar pustulosis under secukinumab in two patients without psoriasis","volume":"20","author":"Penalba-Torres M","year":"2022","unstructured":"Penalba-Torres M, Rivera-D\u00edaz R. Palmoplantar pustulosis under secukinumab in two patients without psoriasis. J Dtsch Dermatol Ges. 2022, 20:106-9. 10.1111\/ddg.14639","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782816","article-title":"Secukinumab retreatment associated psoriasis flare with pustules","volume":"33","author":"El-Komy M","year":"2022","unstructured":"El-Komy M, Amer M, Mostafa A, ElKalioby M. Secukinumab retreatment associated psoriasis flare with pustules. J Dermatolog Treat. 2022, 33:1107-10. 10.1080\/09546634.2020.1782816","journal-title":"J Dermatolog Treat"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4274\/turkderm.galenos.2022.39591","article-title":"Secukinumab-induced paradoxical palmoplantar pustular psoriasis","volume":"56","author":"Urun Y","year":"2022","unstructured":"Urun Y, Yelgen H, Urun M, Can N. Secukinumab-induced paradoxical palmoplantar pustular psoriasis. Turkderm-Turk Arch Dermatol Venereol. 2022, 56:197-9. 10.4274\/turkderm.galenos.2022.39591","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"ref21","article-title":"Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab","volume":"2","author":"Anghel D","year":"2023","unstructured":"Anghel D, Georgescu M, Poenaru M, Orleanu D, Tiplica G. Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab. JEADV Clin Pract. 2023, 2:951-4.","journal-title":"JEADV Clin Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy MJ","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022, 86:1080-91. 10.1016\/j.jaad.2020.12.010","journal-title":"J Am Acad Dermatol"},{"key":"ref23","unstructured":"REMICADE\u00ae (infliximab) for IV injection FDA. (2023). Accessed. November 30, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103772s5258lbl.pdf."},{"key":"ref24","unstructured":"Washout periods for biologics. NHS Dorset. (2020). Accessed: November 30, 2023: https:\/\/www.nhsdorset.nhs.uk\/Downloads\/aboutus\/medicines-management\/Other%20Guidelines\/Washout%20Periods%20for%20Biol...."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0067","article-title":"Paradoxical reactions to biologicals in chronic inflammatory systemic diseases","volume":"119","author":"Kremenevski I","year":"2022","unstructured":"Kremenevski I, Sander O, Sticherling M, Raithel M. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 2022, 119:88-95. 10.3238\/arztebl.m2022.0067","journal-title":"Dtsch Arztebl Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/215888-paradoxical-psoriasis-and-worsening-spondylitis-due-to-secukinumab-in-a-patient-with-ankylosing-spondylitis-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:39Z","timestamp":1707509439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/215888-paradoxical-psoriasis-and-worsening-spondylitis-due-to-secukinumab-in-a-patient-with-ankylosing-spondylitis-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.50726","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}